Invivyd (IVVD) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Pyxis Oncology (PYXS) has outperformed Invivyd (IVVD) over the past year, losing 31.6% versus a loss of 57.3%. Over five years, PYXS leads with a -83.1% price change compared with -97.8% for IVVD. Pyxis Oncology is the larger company by market cap ($243.7 million vs $213.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IVVD | PYXS |
|---|---|---|
| Share price | $0.7245 | $2.04 |
| Market cap | $213.55M | $243.69M |
| 1-day change | +3.45% | +2.51% |
| YTD return | -71.64% | +73.04% |
| 1-year return | -57.29% | -31.62% |
| 5-year return | -97.84% | -83.09% |
| EPS (TTM) | $-0.33 | $-1.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.07 | $5.55 |
| 52-week low | $0.528 | $1.03 |
| Distance from 52-week high | -76.40% | -63.24% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1280.26% | +325.00% |
| Average volume | 4.90M | 1.26M |
| Shares outstanding | 294.76M | 119.46M |
| Employees | 122 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PYXS has outperformed IVVD by 25.7 percentage points over the past year.
About Invivyd
IVVD stock →Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 122 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
IVVD vs PYXS FAQ
Which is bigger, Invivyd or Pyxis Oncology?
Pyxis Oncology (PYXS) is larger, with a market capitalization of $243.69M compared with $213.55M for Invivyd (IVVD).
Which stock has performed better over the past year, IVVD or PYXS?
PYXS returned -31.62% over the past 12 months, compared with -57.29% for IVVD (price return, excluding dividends). Past performance does not predict future results.
Are Invivyd and Pyxis Oncology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Invivyd and Biotechnology: Pharmaceutical Preparations for Pyxis Oncology.